Your shopping cart is currently empty

14,15-Epoxyeicosatrienoic acid (14,15-EET), derived from Arachidonic acid metabolism, significantly inhibits platelet aggregation in vivo and enhances astrocytic Aβ clearance, making it relevant for Alzheimer's Disease research [1][2].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | 8-10 weeks | 8-10 weeks | |
| 50 mg | Inquiry | 8-10 weeks | 8-10 weeks |
| Description | 14,15-Epoxyeicosatrienoic acid (14,15-EET), derived from Arachidonic acid metabolism, significantly inhibits platelet aggregation in vivo and enhances astrocytic Aβ clearance, making it relevant for Alzheimer's Disease research [1][2]. |
| In vitro | 14,15-Epoxyeicosatrienoic acid (0-10 μM) enhances Aβ uptake in primary astrocyte cultures [1]. |
| In vivo | 14,15-Epoxyeicosatrienoic acid (0.3 mg/kg i.v.) inhibits platelet aggregation in murine cerebral arterioles [2]. Administration of 14,15-Epoxyeicosatrienoic acid (200 ng/ml) into the hippocampus reverses Aβ deposition in the brains of 6-month-old male FAD mice [1]. |
| Synonyms | 14,15-EET |
| Molecular Weight | 320.47 |
| Formula | C20H32O3 |
| Cas No. | 81276-03-1 |
| Smiles | O=C(O)CCCC=CCC=CCC=CCC1OC1CCCCC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.